摘要
目的：探讨冷沉淀在颅底骨折出血的临床应用价值，为临床治疗提供借鉴。方法选择80例符合入组标准的颅底骨折出血患者为研究对象，按随机数字表法分为观察组40例和对照组40例，对照组给予止血、脱水、护胃、抗菌、营养神经、降低颅内压、头高位卧床及其他对症治疗，观察组在对照组的基础上再加用冷沉淀止血，每次输10 U，每6～8小时输1次，根据病情输冷沉淀1～3次，符合手术指征者进行手术治疗，治疗后24 h 复查凝血指标[凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、凝血酶时间（TT）、D-二聚体]、血浆纤维蛋白原含量（Fbg），治疗结束后进行国际格拉斯哥预后评分（GOS），观察两组临床预后情况。结果观察组和对照组治疗后 PT、APTT、TT 均明显短于治疗前（t ＝6.654、5．746、6．193和3．342、3．552、3.646，P ＜0．01或 P ＜0．05），观察组 PT、APTT、TT 明显短于对照组（t ＝3．322、3．406、3．315，均 P ＜0．05）。观察组和对照组治疗后 Fbg 均明显高于治疗前（t ＝5．762和3．592，P ＜0．01或 P ＜0．05），观察组治疗后 Fbg 明显高于对照组（t ＝3．407，P ＜0．05）。观察组治疗后临床预后明显优于对照组，差异有统计学意（χ^2＝8．747， P ＜0.05）。结论冷沉淀是一种安全、快捷、疗效好的成分血制剂，能够有效改善颅底骨折出血患者凝血功能障碍，激活内源凝血系统，提高止血效果，减少进展性脑出血的发生，从而改善患者预后。
Objective To investigate the cryoprecipitate fracture hemorrhage clinical application value in the skull fracture hemorrhage,and provide reference for clinical treatment.Methods 80 patients with standard skull frac-ture hemorrhage were selected as the research subjects.The patients were randomly divided into observation group （40 cases）and the control group （40 cases）.The control group was given hemostasis,dehydration,protecting stom-ach,antibacterial,nerve nutrition,reducing intracranial pressure,head up in bed and other symptomatic treatment.The observation group received the treatment besides in the control group and added the cryoprecipitate hemostasis,every time given 10U,every 6 -8h 1 time.According to the condition,they were given the cold sediment of 1 -3 times. Then,the cases that fit to give surgery we must cured them by the operation.After treatment 24h,the coagulation inde-xes were examined [prothrombin time （PT）,activated partial thromboplastin time （APTT）,thrombin time （TT）,two D -dimer],plasma fibrinogen （Fbg）,International Glasgow （GOS）.Finally,we observed clinical prognosis in two groups.Results PT,APTT,TT were significantly shorter than before treatment in the observation group and the con-trol group（t =6.654,5.746,6.193 and 3.342,3.552,3.646,P 〈0.01 or P 〈0.05）.The PT,APTT and TT of the observation group were significantly shorter than those in the control group （t =3.322,3.406,3.315,all P 〈0.05）. Plasma Fbg was significantly higher than before treatment in two groups（t =5.762,3.592,P 〈0.01 or P 〈0.05）. Fbg in the observation group was significantly higher than the control group（t =3.407,P 〈0.05）.The clinical prog-nosis in the observation group was significantly better than the control group（χ^2 =8.747,P 〈0.05）.Conclusion Cryoprecipitate is a safe and efficient drug.It can effectively improve the blood coagulation dysfunction of patients with fracture of skull base,active endogenous coagulation system,improve hemostatic effect,and reduce the occurrence of progressive cerebral hemorrhage.Therefore,it can improve the prognosis of patients.
出处
《中国基层医药》
CAS
2016年第10期1497-1499,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
颅底骨折
出血
冷沉淀
Skull fracture
Hemorrhage
Cryoprecipitate
